The litigation centers on claims that Erasca artificially inflated its business prospects by utilizing improper comparisons between its ERAS-0015 therapy and products developed by Revolution Medicines, Inc. According to the complaint, these actions not only misled shareholders but also exposed the company to significant legal risks regarding patent infringement and trade secret misappropriation. The conflict surfaced on April 27, 2026, when Erasca disclosed in a Form 8-K filing that it had received a legal challenge from Revolution Medicines concerning U.S. Patent No. 12,409,225.

Revolution Medicines specifically challenged the integrity of public disclosures that contrasted ERAS-0015 with its own RMC-6236 candidate, demanding that Erasca retract what it termed deceptive comparative statements. Erasca has publicly maintained that the allegations lack merit and intends to contest the claims. Following the disclosure, the company's stock price dropped from $21.49 on April 24, 2026, to $19.15 by April 27, 2026. Shareholders seeking to serve as lead plaintiffs in the pending litigation are encouraged to contact Robbins LLP, as the firm operates on a contingency fee basis for all participants.